Lung Carcinoma — Trials

Lung Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,130
Recruiting: 1,129
Ph III recruiting: 164
Growth YoY: +1.2%
Industry share: 43%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,177)

clinicaltrialsPublishedShowing 51–53 of 53 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05767892	YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations	not yet recruiting	Phase 3	350	Suzhou Puhe Pharmaceutical Technology Co., LTDINDUSTRY	1	Apr 5, 2023	clinicaltrials
NCT04772287	Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)	not yet recruiting	Phase 3	341	Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER	0